| 61.61 0.13 (0.21%) | 10-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 74.27 | 1-year : | 86.75 |
| Resists | First : | 63.59 | Second : | 74.27 |
| Pivot price | 59.97 |
|||
| Supports | First : | 58.99 | Second : | 56.15 |
| MAs | MA(5) : | 61.77 |
MA(20) : | 60.21  |
| MA(100) : | 60.72 |
MA(250) : | 56.6 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 79 |
D(3) : | 81.2 |
| RSI | RSI(14): 52.1 |
|||
| 52-week | High : | 67.93 | Low : | 40.7 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BMY ] has closed below upper band by 24.3%. Bollinger Bands are 15.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 62.12 - 62.42 | 62.42 - 62.68 |
| Low: | 60.39 - 60.74 | 60.74 - 61.04 |
| Close: | 61.09 - 61.63 | 61.63 - 62.09 |
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Mon, 26 Oct 2026
Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings? - TradingView
Mon, 26 Oct 2026
Bristol-Myers Squibb (NYSE:BMY): Weighing Dividend Quality for Income Investors - ChartMill
Mon, 26 Oct 2026
Bristol Myers Iza-Bren Phase 3 PFS Reaches 11.1 Months - grafa.com
Mon, 26 Oct 2026
Pathos AI Raises $237M at $3B Valuation in Round Led by Bristol Myers Squibb - citybiz
Sun, 25 Oct 2026
Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings? - The Motley Fool
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 2,040 (M) |
| Shares Float | 2,040 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 84.8 (%) |
| Shares Short | 45,850 (K) |
| Shares Short P.Month | 44,070 (K) |
| EPS | 4.53 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.93 |
| Profit Margin | 18.8 % |
| Operating Margin | 34.4 % |
| Return on Assets (ttm) | 10.7 % |
| Return on Equity (ttm) | 46.5 % |
| Qtrly Rev. Growth | 5.6 % |
| Gross Profit (p.s.) | 17.27 |
| Sales Per Share | 24.11 |
| EBITDA (p.s.) | 9.27 |
| Qtrly Earnings Growth | 153.1 % |
| Operating Cash Flow | 12,780 (M) |
| Levered Free Cash Flow | 8,110 (M) |
| PE Ratio | 13.57 |
| PEG Ratio | 17.1 |
| Price to Book value | 5.63 |
| Price to Sales | 2.55 |
| Price to Cash Flow | 9.83 |
| Dividend | 0.62 |
| Forward Dividend | 0 |
| Dividend Yield | 1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|